NCT06959511View on ClinicalTrials.gov

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

October 1, 2029

Conditions
Neoadjuvant TreatmentThyroid Cancer
Interventions
DRUG

Zanzalintinib

Given by po

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT06959511 - Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery | Biotech Hunter | Biotech Hunter